- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
UK First Country to Approve Merck’s COVID-19 Pill
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for Merck and Ridgeback Therapeutics’ molnupiravir (to be trademarked LAGEVRIO in the UK). Results from an interim analysis from the Phase III MOVe-OUT clinical trial showed that the oral treatment could halve the risk of hospitalization or death for adults with a positive SARS-CoV-2 diagnostic test and mild to moderate COVID symptoms and who had at least one risk factor have at least one risk factor for developing severe illness.
The approval is ”a major achievement in Merck’s singular legacy of bringing forward breakthrough medicines and vaccines to address the world’s greatest health challenges,“ said Robert M. Davis, the company’s chief executive officer and president.
Wendy Holman, chief executive officer of Ridgeback Biotherapeutics, commented: ”It is also gratifying to see the first global authorization occur in the UK, the very place where we administered molnupiravir to the first brave human volunteer.”
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Artificial Intelligence Makes Possible a Multiomic Approach in Oncology Drug Discovery
January 7th 2025While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates more quickly and efficiently with applications in target discovery, structure prediction, and drug optimization.
